A new drug based on psilocybin, the psychoactive ingredient in “magic mushrooms”, has been fast tracked by the FDA as a novel theraputic. This designation marks a huge swing in the attitude of the US FDA toward psychedelic drugs for clinical purposes.
- Is the FDA right to explore psychedelic drugs for therapies?
- Have you tried magic mushrooms in the past?
- Would you take a clinical drug based on psilocybin if recommended by a doctor?
The FDA granted researchers the designation of “breakthrough therapy” to study mushrooms.
For the first time in U.S. history, a psychedelic drug is on the fast track to getting approved for treating depression by the federal government. Late last month, Compass Therapeutics, a U.K.-based company that researches and develops mental health treatments, announced the FDA granted them what’s called a “breakthrough therapy designation” for their trials into psilocybin, the psychoactive ingredient in psychedelic mushrooms.
Pioneering psychedelic science researchers agree – this is a landmark moment in their field.
“It really represents an important development throughout the history of psychedelic research,” says Charles Grob, professor of psychiatry and behavioral sciences at the University of California, Los Angeles, who conducted basic psilocybin studies at UCLA in the mid-2000s.